Ziconotide Evidence Guide
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.
Our Take
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.
- Best for
- Severe chronic refractory pain (intrathecal), N-type calcium channel pharmacology, non-opioid analgesic research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.1mcg/hour intrathecal (starting dose, titrated slowly to max 19.2mcg/day) - requires intrathecal pump
Benefits and Evidence
- Severe Chronic Pain Relief: Level A, includes human evidence - Phase 3 trials demonstrated significant pain reduction (VASPI scores) in patients with severe chronic pain refractory to other therapies, including those with cancer and non-cancer pain.
- Opioid-Sparing Effect: Level B, includes human evidence - Allows reduction or elimination of intrathecal opioids in some patients, reducing opioid-related side effects while maintaining analgesia.
- Neuropsychiatric Side Effects: Level A, includes human evidence - Cognitive impairment, hallucinations, and psychiatric symptoms are significant dose-limiting adverse effects requiring careful dose titration.
Side Effects and Warnings
- Dizziness
- Nausea
- Confusion and cognitive impairment
- Nystagmus
- Hallucinations
- Gait disturbance
- Urinary retention
- Severe psychiatric symptoms (psychosis, suicidal ideation) - discontinue if these occur
Research Dosage References
- <strong>Intrathecal infusion</strong> - 0.1-19.2 mcg/day - Continuous via implanted pump - Start at 2.4 mcg/day or less. Titrate slowly - no more than 2.4 mcg/day increase, no more than 2-3 times per week. Maximum recommended: 19.2 mcg/day.
Mechanism of Action
Ziconotide provides analgesia through selective calcium channel blockade: 1. N-type calcium channel (Cav2.2) blockade: Selectively and reversibly blocks pre-synaptic N-type voltage-gated calcium channels in the dorsal horn of the spinal cord. 2. Neurotransmitter release inhibition: Prevents calcium influx required for vesicle fusion and release of pain-transmitting neurotransmitters (substance P, glutamate, CGRP) from primary afferent nociceptive neurons. 3. Non-opioid mechanism: Acts independently of opioid receptors, making it effective in opioid-tolerant patients and carrying no risk of respiratory depression or addiction.
Legal Status
FDA-approved (2004) for management of severe chronic pain in patients intolerant of or refractory to other therapies. Schedule V controlled substance. Marketed as Prialt by Jazz Pharmaceuticals.
Primary Sources
- Intrathecal ziconotide in the treatment of refractory pain. JAMA, 2004.
- A randomized, double-blind, placebo-controlled trial of ziconotide for chronic pain. Pain, 2006.
- Ziconotide: a review of its pharmacology and use in chronic pain. Neurotherapeutics, 2007.